Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicotinate
Drug ID BADD_D01563
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Marketing Status Prescription; Discontinued
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 937
TTD Drug ID Not Available
NDC Product Code 59651-018; 65162-322; 71740-001; 65372-1194; 47335-539; 59746-387; 51552-0559; 0074-3265; 59746-380; 68180-222; 0074-3275; 62175-322; 62331-016; 62704-0027; 33342-187; 59651-020; 72919-420; 47335-614; 68180-221; 68180-223; 25441-0095; 0074-3274; 50268-584; 71740-201; 71741-020; 71741-047; 51407-268; 59746-381; 47335-613; 62175-320; 33342-189; 51407-267; 59651-019; 63629-7193; 65162-321; 65162-323
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H4NO2-
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.001--Not Available
Macular oedema06.04.06.005--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mucous membrane disorder08.01.06.004--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Neoplasm skin16.03.02.003; 23.08.02.003--Not Available
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophagitis07.08.05.001--
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Pain08.01.08.004--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Peptic ulcer07.04.07.001--Not Available
Polyuria20.02.03.002--Not Available
Prostatic disorder21.04.01.001--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rash pustular23.03.10.003; 11.01.12.002--
Rhabdomyolysis15.05.05.002--
Rhinitis22.07.03.006; 11.01.13.004--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages